153 results on '"Varadhachary G"'
Search Results
2. High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients
3. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes
4. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients
5. Margin Status Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: Implications of R Status
6. Resected Pancreatic Cancer
7. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset
8. CT imaging features of acinar cell carcinoma and its hepatic metastases
9. The integration of chemoradiation in the care of patient with localized pancreatic cancer
10. Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases
11. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy†
12. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes
13. The sequential radiographic effects of preoperative chemotherapy and (chemo)radiation on tumor anatomy in patients with localized pancreatic cancer
14. Spontaneous pneumothorax in malignancy: A case report and review of the literature
15. Low volume institutions are associated with delay and omission of adjuvant chemotherapy for resected pancreatic adenocarcinoma independent of surgical approach
16. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?
17. Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma
18. Resected Pancreatic Cancer
19. Margin Status Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: Implications of R Status
20. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset
21. CT imaging features of acinar cell carcinoma and its hepatic metastases
22. Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases
23. Clinical utility of gene-expression profiling for tumor site origin.
24. Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer.
25. Patients with carcinoma of unknown primary with isolated carcinomatosis on presentation: Clinicopathologic features and survival data.
26. Carcinoma of unknown primary site (CUP): Outcomes in patients with a colorectal molecular profile treated with site-specific chemotherapy.
27. Relative value of serum cytokines and clinical factors in predicting weight loss in advanced pancreatic cancer (PC).
28. Comparison of ampullary adenocarcinomas and duodenal adenocarcinomas with regard to clinical outcomes and responsiveness to fluoropyrimidine-based chemotherapy.
29. Use of DPC-4 immunostaining of diagnostic cytology specimens to predict the pattern of tumor progression in locally advanced pancreatic cancer patients (LAPC).
30. Effect of a gene expression-based tissue of origin test's impact on patient management for difficult-to-diagnose primary cancers.
31. Use of gene expression analysis of periampullary carcinomas to identify biliary-like and intestinal-like subgroups of ampullary and duodenal carcinomas.
32. Multi-institutional Phase II Trial of Induction Cetuximab Gemcitabine and Oxaliplatin, followed by Radiotherapy with Concurrent Capecitabine, and Cetuximab, for Locally Advanced Pancreatic Adenocarcinoma (LAPC)
33. Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms.
34. Neoadjuvant versus upfront surgical strategies in patients with resectable pancreatic adenocarcinoma: A decision analysis.
35. Cost-effectiveness of neoadjuvant (NeoAdj) versus adjuvant (Adj) therapies for resectable pancreatic cancer (PC).
36. Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer.
37. Prospective gene signature study using microRNA to predict the tissue of origin (ToO) in pts with cancer of unknown primary site (CUP).
38. Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: The results of two prospective phase II studies
39. PHASE II STUDY OF MTOR-INHIBITOR RAD001 AND ERLOTINIB FOR ADVANCED, GEMCITABINE-REFRACTORY PANCREATIC CANCER
40. 328 POSTER Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer
41. Preoperative gemcitabine (gem) and bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma
42. A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer
43. Final response data of a phase II study of capecitabine and oxaliplatin (CAPOX) in advanced adenocarcinoma of the small bowel or ampulla of Vater
44. Prospective study of a 10-gene molecular assay to predict tissue of origin in patients with carcinoma of unknown primary (CUP)
45. Gene profiling validation for cancer classification using known primary carcinoma samples
46. 1076
47. A phase II trial of oxaliplatin plus capecitabine (xelox) as second line therapy for patients with advanced pancreatic cancer
48. Retrospective review of patients with adenocarcinoma of the pancreas and ovarian metastasis: Clinical characteristics, treatment strategies, and survival data
49. Neoadjuvant chemotherapy improves outcomes of chemoradiation therapy for locally advanced pancreatic cancer
50. Interim results of preoperative gemcitabine (gem) plus cisplatin followed by rapid fractionation chemoradiation for resectable pancreatic adenocarcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.